Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer Disease
Top Cited Papers
Open Access
- 15 November 2005
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 2 (12) , e355
- https://doi.org/10.1371/journal.pmed.0020355
Abstract
The proteases (secretases) that cleave amyloid-β (Aβ) peptide from the amyloid precursor protein (APP) have been the focus of considerable investigation in the development of treatments for Alzheimer disease. The prediction has been that reducing Aβ production in the brain, even after the onset of clinical symptoms and the development of associated pathology, will facilitate the repair of damaged tissue and removal of amyloid lesions. However, no long-term studies using animal models of amyloid pathology have yet been performed to test this hypothesis. We have generated a transgenic mouse model that genetically mimics the arrest of Aβ production expected from treatment with secretase inhibitors. These mice overexpress mutant APP from a vector that can be regulated by doxycycline. Under normal conditions, high-level expression of APP quickly induces fulminant amyloid pathology. We show that doxycycline administration inhibits transgenic APP expression by greater than 95% and reduces Aβ production to levels found in nontransgenic mice. Suppression of transgenic Aβ synthesis in this model abruptly halts the progression of amyloid pathology. However, formation and disaggregation of amyloid deposits appear to be in disequilibrium as the plaques require far longer to disperse than to assemble. Mice in which APP synthesis was suppressed for as long as 6 mo after the formation of Aβ deposits retain a considerable amyloid load, with little sign of active clearance. This study demonstrates that amyloid lesions in transgenic mice are highly stable structures in vivo that are slow to disaggregate. Our findings suggest that arresting Aβ production in patients with Alzheimer disease should halt the progression of pathology, but that early treatment may be imperative, as it appears that amyloid deposits, once formed, will require additional intervention to clear.Keywords
This publication has 63 references indexed in Scilit:
- Tau Suppression in a Neurodegenerative Mouse Model Improves Memory FunctionScience, 2005
- Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic miceExperimental Neurology, 2004
- Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administrationNeurobiology of Disease, 2003
- Genetics of Early-Onset Alzheimer DementiaThe Scientific World Journal, 2003
- Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic miceNeurobiology of Aging, 2001
- Control of Memory Formation Through Regulated Expression of a CaMKII TransgeneScience, 1996
- A vector for expressing foreign genes in the brains and hearts of transgenic miceGenetic Analysis: Biomolecular Engineering, 1996
- Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In VivoNeuron, 1996
- Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.Proceedings of the National Academy of Sciences, 1996
- Alzheimer's Disease: The Amyloid Cascade HypothesisScience, 1992